NeuPath's $420K Share Deal: Reward for Turnaround or Governance Test?

TORONTO, ON – April 01, 2026 – NeuPath Health Inc. (TSXV:NPTH), a major operator of Canadian pain management clinics, has proposed a plan to settle $420,000 in executive bonuses by issuing company stock, a move that highlights both a remarkable corporate turnaround and raises important questions of corporate governance that will soon be put to a shareholder vote.

The company announced its intention to issue 893,616 common shares to settle debt owed to its former Chief Executive Officer, Joseph Walewicz, and its current Chief Financial Officer, Jeff Zygouras. The settlement covers a portion of performance-based bonuses earned during a three-year period that saw the company dramatically improve its financial health. While the move is presented as a reward for steering the company out of difficulty, its structure as a “related party transaction” means it must secure the approval of disinterested shareholders at a special meeting scheduled for June 10, 2026.

The Turnaround and the Reward

The proposed share issuance is directly tied to a Long-Term Incentive (LTI) Award established when NeuPath was navigating significant financial headwinds. The performance period, running from January 1, 2023, to December 31, 2025, was a crucible for the company's leadership. At the start of this period, following the 2022 fiscal year, NeuPath was in a precarious position with a net debt of $3.1 million on revenues of $62.7 million and an Adjusted EBITDA of just $2.3 million.

By the end of the performance period, the company’s fortunes had reversed dramatically. Revenue surged by 39% to $87.2 million, and Adjusted EBITDA skyrocketed by an impressive 161% to $6.0 million. Crucially, the company's net debt position improved significantly to $1.7 million. This financial recovery forms the backbone of the justification for the bonus payout. The LTI Award was specifically designed as a performance and retention tool, and by all stated metrics, the executives delivered.

By opting to settle this debt with shares rather than cash, NeuPath conserves its capital, a prudent move for a company still focused on executing its growth strategy. The shares are to be issued at a deemed price of $0.47, reflecting the company’s closing stock price on March 31, 2026. This method aligns the interests of the executives with those of shareholders, as the value of their compensation becomes directly tied to the company's future stock performance.

A Matter of Governance

While the financial turnaround is clear, the method of compensation introduces layers of regulatory and governance scrutiny. The transaction is officially classified as a “related party transaction” under Canadian securities laws, including Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9. These rules are designed to protect minority shareholders from deals that could potentially favor insiders.

Interestingly, the settlement is exempt from the most stringent requirements of MI 61-101—such as a formal valuation and mandatory minority shareholder approval—because the value of the transaction does not exceed 25% of NeuPath’s market capitalization. However, a different rule, Exchange Policy 4.4, kicks in. This policy mandates disinterested shareholder approval for any security-based compensation to non-arm’s length parties that exceeds $10,000 per month.

This means that when shareholders vote in June, the shares held by Walewicz, Zygouras, and any other related or non-independent parties will not be counted. The decision will rest solely in the hands of the company's independent, or “disinterested,” investors. The board's independent members have already approved the settlement, noting that no special committee was formed and no directors expressed contrary views. This indicates internal consensus but shifts the final gatekeeping responsibility to the shareholders themselves, who must weigh the merits of the performance against the precedent of paying insider bonuses with potentially dilutive stock.

Insider Confidence and Strategic Direction

Beyond the mechanics of the deal, the decision by executives to accept shares is being framed as a powerful vote of confidence in NeuPath’s future. Upon completion of the settlement, insider ownership by the board and management will rise to 13%, a significant alignment of interests that can be a bullish signal for the market.

This sentiment was echoed by Jolyon Burton, a key figure in the NeuPath story. As a Director, Chairman, and co-founder of the influential healthcare investment firm Bloom Burton & Co., his perspective carries weight. “On behalf of the Board and shareholders, I would like to thank Mr. Walewicz and Mr. Zygouras for their hard work and relentless dedication as they navigated NeuPath through some difficult times, and for accepting NeuPath shares as payment for the Debt,” Burton stated in the press release. He added that the company is now “perfectly set up for Stephen Lemieux and the team to execute on our growth strategy.” Stephen Lemieux has since taken the helm as the new CEO, tasked with building on the stable foundation his predecessors helped create.

Burton’s role itself adds a layer of complexity. His firm, Bloom Burton & Co., has been a long-time shareholder and financial partner to NeuPath, and public filings have shown an ongoing financial relationship. While his influence and expertise are undeniable assets, this deep-rooted connection underscores the interconnected nature of the company’s leadership and its key financial backers, a factor that discerning investors will likely consider ahead of the vote.

The market’s initial reaction to the news was muted but slightly positive, suggesting that investors may be willing to accept the board's rationale. However, the true test will come at the June meeting. Shareholders will have to decide if this shares-for-debt settlement is a fair and justified reward for a job well done, or if it sets a concerning precedent for executive compensation and corporate governance within the company.